Results from the Phase III PURPOSE 1 (NCT04994509) and PURPOSE 2 (NCT04925752) trials highlight Yeztugo’s (lenacapavir) ...

Northwell Health in Manhasset is offering an FDA-approved drug called Yeztugo, which is taken twice a year. Stephen Colbert's ...

Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

Researchers wanted to provide insight into the relative clinical value of Apretude and lenacapavir compared with no ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 ...

The WHO’s Director-General described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the ...

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be HIV-negative to get it.

"Analysis shows Yeztugo approval a ‘momentous step’ for HIV prevention" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say about it.

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show prevents new infections.

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...